SG11201406032TA - Prophylactic or therapeutic agent for giant cell tumors occuring in bone and soft tissue or for chondrosarcoma - Google Patents

Prophylactic or therapeutic agent for giant cell tumors occuring in bone and soft tissue or for chondrosarcoma

Info

Publication number
SG11201406032TA
SG11201406032TA SG11201406032TA SG11201406032TA SG11201406032TA SG 11201406032T A SG11201406032T A SG 11201406032TA SG 11201406032T A SG11201406032T A SG 11201406032TA SG 11201406032T A SG11201406032T A SG 11201406032TA SG 11201406032T A SG11201406032T A SG 11201406032TA
Authority
SG
Singapore
Prior art keywords
chondrosarcoma
occuring
prophylactic
bone
therapeutic agent
Prior art date
Application number
SG11201406032TA
Other languages
English (en)
Inventor
Akihiko Takeuchi
Hiroyuki Tsuchiya
Original Assignee
Nippon Chemiphar Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Chemiphar Co filed Critical Nippon Chemiphar Co
Publication of SG11201406032TA publication Critical patent/SG11201406032TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Genetics & Genomics (AREA)
SG11201406032TA 2012-03-26 2013-03-18 Prophylactic or therapeutic agent for giant cell tumors occuring in bone and soft tissue or for chondrosarcoma SG11201406032TA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2012070351 2012-03-26
JP2012235784 2012-10-25
PCT/JP2013/057706 WO2013146435A1 (ja) 2012-03-26 2013-03-18 骨・軟部に発生する巨細胞性腫瘍または軟骨肉腫の予防または治療剤

Publications (1)

Publication Number Publication Date
SG11201406032TA true SG11201406032TA (en) 2014-11-27

Family

ID=49259696

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201406032TA SG11201406032TA (en) 2012-03-26 2013-03-18 Prophylactic or therapeutic agent for giant cell tumors occuring in bone and soft tissue or for chondrosarcoma

Country Status (11)

Country Link
US (1) US10660882B2 (ja)
EP (1) EP2832367B1 (ja)
JP (2) JP5865995B2 (ja)
KR (1) KR102199273B1 (ja)
CN (2) CN106267210A (ja)
AU (1) AU2013238126C1 (ja)
CA (1) CA2868311C (ja)
HK (1) HK1203818A1 (ja)
NZ (1) NZ700872A (ja)
SG (1) SG11201406032TA (ja)
WO (1) WO2013146435A1 (ja)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10660882B2 (en) 2012-03-26 2020-05-26 Nippon Chemiphar Co., Ltd. Prophylactic or therapeutic agent for giant cell tumors occurring in bone and soft tissue or for chondrosarcoma
EP3632428A1 (en) * 2013-09-25 2020-04-08 Nippon Chemiphar Co., Ltd. Zaltoprofen for use in the prophylactic or therapeutic treatment of giant cell tumors occurring in bone and soft tissue or of chondrosarcoma
CN103599093B (zh) * 2013-11-18 2016-06-01 中国医学科学院生物医学工程研究所 一种抗hpv药物制剂及用途
BR112017013111A2 (pt) * 2014-12-22 2018-05-15 Five Prime Therapeutics Inc métodos de tratamento de um distúrbio e de tratamento da sinovite, uso de um anticorpo e anticorpo
JP6703824B2 (ja) * 2015-11-30 2020-06-03 シスメックス株式会社 細胞選択方法、細胞検出方法、細胞選択装置、および細胞検出装置
EP3383384A4 (en) * 2015-12-01 2019-08-07 Theriac Biomedicale Inc. PPAR-GAMMA ACTIVATORS AND THEIR THERAPEUTIC USES
KR102650228B1 (ko) 2021-10-06 2024-03-21 단국대학교 천안캠퍼스 산학협력단 이온이 담지된 생활성 유리 나노입자 및 이의 제조방법
CN116875550B (zh) * 2023-09-08 2023-12-26 天津市肿瘤医院（天津医科大学肿瘤医院） 一种FABP4+C1q+巨噬细胞及其制备方法和用途

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06192084A (ja) 1992-06-30 1994-07-12 Kaken Pharmaceut Co Ltd 癌転移抑制剤
US5753702A (en) 1996-05-22 1998-05-19 University Of Vermont Arachidonic acid metabolite, 16-hete
US6984735B2 (en) 2001-12-03 2006-01-10 Wyeth Process for making an aldehyde
US7605156B2 (en) 2001-12-03 2009-10-20 Wyeth Methods for the use of inhibitors of cytosolic phospholipase A2
US6635771B2 (en) 2001-12-03 2003-10-21 Wyeth N-benzhydryl indole compounds
US7101875B2 (en) * 2001-12-03 2006-09-05 Wyeth Methods for treating arthritic disorders
US6797708B2 (en) 2001-12-03 2004-09-28 Wyeth Inhibitors of cytosolic phospholipase A2
US7713964B2 (en) 2001-12-03 2010-05-11 Wyeth Llc Methods for treating asthmatic conditions
US20030220374A1 (en) 2002-01-14 2003-11-27 Pharmacia Corporation Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors
DE10237571A1 (de) * 2002-08-13 2004-02-26 Biotronik Meß- und Therapiegeräte GmbH & Co. Ingenieurbüro Berlin Endovaskuläres Implantat mit aktiver Beschichtung
US20060240014A1 (en) 2003-06-03 2006-10-26 Beth Israel Deaconess Medical Center Methods and compounds for the treatment of vascular stenosis
JP2007015930A (ja) * 2004-09-13 2007-01-25 Ono Pharmaceut Co Ltd 複素ビシクロ環および複素トリシクロ環化合物およびその医薬
JP2005200419A (ja) 2004-01-16 2005-07-28 National Health Research Inst 癌治療法
EP1739081A1 (en) 2004-04-21 2007-01-03 Ono Pharmaceutical Co., Ltd. Hydrazino-substituted heterocyclic nitrile compounds and use thereof
JP4179219B2 (ja) 2004-05-14 2008-11-12 松下電器産業株式会社 電気湯沸かし器
JP2005343802A (ja) 2004-05-31 2005-12-15 Norifumi Sakayama 非ステロイド性消炎鎮痛剤の外用剤を用いた癌細胞の増殖を抑制する方法
US7250550B2 (en) 2004-10-22 2007-07-31 Wright Medical Technology, Inc. Synthetic bone substitute material
KR100753480B1 (ko) * 2006-01-27 2007-08-31 씨제이 주식회사 잘토프로펜 함유 서방성 정제 및 그 제조방법
PE20080038A1 (es) * 2006-04-11 2008-02-22 Smithkline Beecham Corp Derivados de tiazolidinadiona como inhibidores de la pi3 quinasa
JP5219147B2 (ja) 2006-09-01 2013-06-26 国立大学法人 千葉大学 色素性絨毛結節性滑膜炎及び腱鞘骨巨細胞腫の治療薬
KR20090128454A (ko) 2007-03-07 2009-12-15 얀센 파마슈티카 엔.브이. 에스트로겐 관련 수용체-알파 조절제로서 치환된 페녹시 아미노티아졸론
US7846953B2 (en) 2007-03-07 2010-12-07 Janssen Pharmaceutica, Nv Substituted phenoxy thiazolidinediones as estrogen related receptor-α modulators
KR20090118103A (ko) 2007-03-07 2009-11-17 얀센 파마슈티카 엔.브이. 에스트로겐 관련 수용체-알파 조절제로서 치환된 페녹시 ｎ-알킬화 티아졸리딘디온
KR101815321B1 (ko) 2008-04-15 2018-01-05 라이프 사이언스 엔터프라이즈 칼슘 포스페이트 혼합 골 시멘트를 이용한 척추의 최소 침습적 치료방법
US8906111B2 (en) * 2008-07-02 2014-12-09 The University Of Tokyo Artificial bone material having controlled calcium ion elution
US20130109620A1 (en) 2009-12-18 2013-05-02 Rheoscience A/S Balaglitazone compositions and methods
CA2789757A1 (en) 2010-02-17 2011-08-25 Janssen Pharmaceutica Nv Aminothiazolones as estrogen related receptor-alpha modulators
CA2789753A1 (en) 2010-02-17 2011-08-25 Janssen Pharmaceutica Nv Aminothiazolones as estrogen related receptor-alpha modulators
WO2011149841A1 (en) 2010-05-25 2011-12-01 Janssen Pharmaceutica Nv SUBSTITUTED THIAZOLIDINEDIONE INDAZOLES, INDOLES AND BENZOTRIAZOLES AS ESTROGEN-RELATED RECEPTOR-α MODULATORS
US10660882B2 (en) 2012-03-26 2020-05-26 Nippon Chemiphar Co., Ltd. Prophylactic or therapeutic agent for giant cell tumors occurring in bone and soft tissue or for chondrosarcoma
EP3632428A1 (en) 2013-09-25 2020-04-08 Nippon Chemiphar Co., Ltd. Zaltoprofen for use in the prophylactic or therapeutic treatment of giant cell tumors occurring in bone and soft tissue or of chondrosarcoma
US9907882B2 (en) 2014-04-18 2018-03-06 Warsaw Orthopedic, Inc. Demineralized bone matrix with improved osteoinductivity

Also Published As

Publication number Publication date
CN104302322A (zh) 2015-01-21
KR20140139070A (ko) 2014-12-04
AU2013238126B2 (en) 2017-12-21
JP6205403B2 (ja) 2017-09-27
EP2832367B1 (en) 2020-07-15
CN106267210A (zh) 2017-01-04
US20150045396A1 (en) 2015-02-12
JPWO2013146435A1 (ja) 2015-12-10
CA2868311A1 (en) 2013-10-03
US10660882B2 (en) 2020-05-26
NZ700872A (en) 2016-09-30
WO2013146435A1 (ja) 2013-10-03
CA2868311C (en) 2021-06-22
EP2832367A4 (en) 2015-12-16
JP2016102129A (ja) 2016-06-02
KR102199273B1 (ko) 2021-01-06
JP5865995B2 (ja) 2016-02-17
HK1203818A1 (en) 2015-11-06
AU2013238126A1 (en) 2014-11-06
EP2832367A1 (en) 2015-02-04
AU2013238126C1 (en) 2018-06-14

Similar Documents

Publication Publication Date Title
SG11201406032TA (en) Prophylactic or therapeutic agent for giant cell tumors occuring in bone and soft tissue or for chondrosarcoma
PT2771041T (pt) Composições e suas utilizações na cicatrização óssea
IL226127A0 (en) A compound containing hydrolyzed proteins and an oligosaccharide for the treatment of skin diseases
EP2701621A4 (en) METHODS AND INSTRUMENTS FOR USE IN VERTEBRAL TREATMENT
EP2897625A4 (en) AMNIOTIC MEMBRANE AND USE THEREOF IN WOUND HEALING CONSTRUCTION AND TISSUE ENGINEERING CONSTRUCTS
DK2608777T3 (en) Compositions and Methods for Cardiac Therapy
EP2608746A4 (en) IMPLANTS, SURGICAL METHODS AND INSTRUMENTATION USED IN SURGERY OF THE PRIOR CONFLICT OF THE HIP
EP2633873A4 (en) MEDICAMENT INJECTION DEVICE FOR USE IN SKIN SURGERY
HK1198625A1 (en) Implants and methods of using the implants to fill holes in bone tissue
EP2563426A4 (en) APPLICATION WITH HIGH SCAM FOR MEDICAL THERAPY
PL2371316T3 (pl) Instrument chirurgiczny, zwłaszcza instrument elektrochirurgiczny
ZA201303810B (en) Methods and compositions suitable for promoting healthy skin
EP2640316A4 (en) FABRIC BACKUP DEVICES AND USE METHOD THEREFOR
ZA201504815B (en) Valve assemblies for expandable implants and tissue expanders
EP2544655A4 (en) COMPOSITIONS AND METHODS FOR TREATING SKIN
HK1187345A1 (en) Derivatives of heteroarylsulfonamides, their preparation and their application in human therapy
HK1203338A1 (en) Methods and devices for soft tissue dissection
IL236399B1 (en) Polymerizable compositions and methods of use in vivo
HK1205687A1 (en) Prophylactic and or therapeutic agent for radiation damage
EP2566530A4 (en) DEVICES AND METHODS FOR TISSUE ENGINEERING
EP2837319A4 (en) IN VIVO INTRODUCTION DEVICE AND ENDOSCOPE IN AN IN VIVO INTRODUCTION DEVICE
GB201217230D0 (en) Yarashi bone and plate holding forceps
IL238951B (en) Valve assemblies for implantable prostheses and tissue expanders
EP2903559A4 (en) CONDUCTIVE AND BIODEGRADABLE IMPLANT FOR DENTAL TISSUE TREATMENT
HK1203159A1 (en) Prophylactic agent and or therapeutic agent for stress urinary incontinence